AU2002222853A1 - Therapeutic compounds - Google Patents
Therapeutic compoundsInfo
- Publication number
- AU2002222853A1 AU2002222853A1 AU2002222853A AU2285302A AU2002222853A1 AU 2002222853 A1 AU2002222853 A1 AU 2002222853A1 AU 2002222853 A AU2002222853 A AU 2002222853A AU 2285302 A AU2285302 A AU 2285302A AU 2002222853 A1 AU2002222853 A1 AU 2002222853A1
- Authority
- AU
- Australia
- Prior art keywords
- therapeutic compounds
- therapeutic
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25177500P | 2000-12-07 | 2000-12-07 | |
| US25177900P | 2000-12-07 | 2000-12-07 | |
| US60251775 | 2000-12-07 | ||
| US60251779 | 2000-12-07 | ||
| SE0100006A SE0100006D0 (en) | 2001-01-02 | 2001-01-02 | Therapeutic compounds |
| SE0100007 | 2001-01-02 | ||
| SE0100006 | 2001-01-02 | ||
| SE0100007A SE0100007D0 (en) | 2001-01-02 | 2001-01-02 | Therapeutic compounds |
| PCT/SE2001/002724 WO2002046164A1 (en) | 2000-12-07 | 2001-12-07 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002222853A1 true AU2002222853A1 (en) | 2002-06-18 |
Family
ID=27484528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002222853A Abandoned AU2002222853A1 (en) | 2000-12-07 | 2001-12-07 | Therapeutic compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7256201B2 (en) |
| EP (1) | EP1341765A1 (en) |
| JP (1) | JP2004515494A (en) |
| AU (1) | AU2002222853A1 (en) |
| WO (1) | WO2002046164A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10151363A1 (en) * | 2001-10-17 | 2003-05-08 | Schering Ag | Use of estrogen receptor beta agonists to prepare medicaments for producing somatotropic and organotropic effects on the CNS, circulatory, skeletal and immune system in aging men and women |
| AR040126A1 (en) | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | PHENYL SULFONYL COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| ATE384700T1 (en) * | 2004-03-12 | 2008-02-15 | Analytecon Sa | TETRAHYDROISOCINOLINE AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS |
| GEP20094640B (en) | 2004-07-15 | 2009-03-10 | Bristol Myers Squibb Co | Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP1789420A2 (en) | 2004-09-07 | 2007-05-30 | Wyeth, A Corporation of the State of Delaware | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| BRPI0806371A2 (en) | 2007-01-22 | 2011-09-13 | Gtx Inc | nuclear receptor binding agents |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| EP2143714B1 (en) | 2007-04-04 | 2013-06-05 | Kowa Company, Ltd. | Tetrahydroisoquinoline compound |
| JP2010535171A (en) * | 2007-08-02 | 2010-11-18 | エフ．ホフマン−ラ ロシュ アーゲー | Monoamide derivatives as orexin receptor antagonists |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| KR101830447B1 (en) * | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-([1,2,4]TRIAZOLO[1,5-α]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| JP5739415B2 (en) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S) -7-([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline Crystal forms and uses thereof |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| WO2014023329A1 (en) * | 2012-08-06 | 2014-02-13 | Life And Brain Gmbh | Niclosamide and its derivatives for use in the treatment of solid tumors |
| MY173564A (en) | 2013-05-30 | 2020-02-04 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| WO2015024111A1 (en) * | 2013-08-21 | 2015-02-26 | Universite Laval | Compounds for the treatment of hormone-dependent diseases |
| WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| US10202368B2 (en) | 2014-12-01 | 2019-02-12 | Idorsia Pharmaceuticals Ltd. | CXCR7 receptor modulators |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US9834507B2 (en) | 2015-04-21 | 2017-12-05 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| US10035763B2 (en) | 2015-04-21 | 2018-07-31 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10017471B2 (en) | 2015-04-21 | 2018-07-10 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| AU2016250562B2 (en) | 2015-04-21 | 2020-08-13 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| BR112017022860A2 (en) * | 2015-04-21 | 2018-07-17 | Gtx Inc | selective androgen receptor (sard) decomposed ligands and methods of using them |
| CN105218444A (en) * | 2015-11-14 | 2016-01-06 | 刘杰 | A kind of pharmaceutical composition for the treatment of lung cancer |
| TWI728017B (en) | 2015-12-15 | 2021-05-21 | 瑞典商阿斯特捷利康公司 | Isoindole compounds, pharmaceutical composition comprising the same, and uses thereof |
| CN109219604B (en) * | 2016-04-08 | 2021-09-24 | 豪夫迈·罗氏有限公司 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| JP6920759B2 (en) * | 2017-03-03 | 2021-08-18 | 國立臺灣大學 | Compounds and use of compounds |
| WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| PE20231066A1 (en) | 2020-02-07 | 2023-07-17 | Gasherbrum Bio Inc | GLP-1 HETEROCYCLIC AGONISTS |
| CN111825613B (en) * | 2020-08-17 | 2022-02-15 | 上海勋和医药科技有限公司 | Tetrahydroisoquinoline compounds as selective estrogen receptor down-regulation agent, and synthesis method and application thereof |
| CN115108964A (en) * | 2022-05-30 | 2022-09-27 | 成都陈泷张科技有限责任公司 | Phthalide derivative, preparation method and application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU658188B2 (en) * | 1991-05-20 | 1995-04-06 | Tsumura & Co. | Phellodendrine analogs and allergy type IV suppressor containing the same as active ingredient |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| AU766648B2 (en) * | 1999-03-17 | 2003-10-23 | Axys Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6518301B1 (en) | 1999-04-16 | 2003-02-11 | Astrazeneca Ab | Estrogen receptor-β ligands |
| EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
-
2001
- 2001-12-07 US US10/450,023 patent/US7256201B2/en not_active Expired - Fee Related
- 2001-12-07 EP EP01999560A patent/EP1341765A1/en not_active Withdrawn
- 2001-12-07 JP JP2002547903A patent/JP2004515494A/en active Pending
- 2001-12-07 WO PCT/SE2001/002724 patent/WO2002046164A1/en active Application Filing
- 2001-12-07 AU AU2002222853A patent/AU2002222853A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7256201B2 (en) | 2007-08-14 |
| EP1341765A1 (en) | 2003-09-10 |
| JP2004515494A (en) | 2004-05-27 |
| US20050101584A1 (en) | 2005-05-12 |
| WO2002046164A1 (en) | 2002-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002222853A1 (en) | Therapeutic compounds | |
| AU2001252135A1 (en) | Therapeutic agents | |
| GB0023983D0 (en) | Therapeutic compounds | |
| AU2001230426A1 (en) | Therapeutic morpholino-substituted compounds | |
| AU2002221239A1 (en) | Therapeutic benzimidazole compounds | |
| GB0008710D0 (en) | Therapeutic compounds | |
| GB0016681D0 (en) | Therapeutic compounds | |
| AU2002225730A1 (en) | Compounds | |
| AUPQ661800A0 (en) | Insulin-potentiating compounds | |
| GB0028583D0 (en) | Therapeutic compounds | |
| AU2001253362A1 (en) | Novel compounds | |
| AU2002353739A1 (en) | Therapeutic compounds | |
| AU2002225724A1 (en) | Motilide compounds | |
| AU2001273903A1 (en) | Therapeutic agents | |
| AU2002217285A1 (en) | Compounds | |
| AU2001230689A1 (en) | Novel compounds | |
| AU2001275696A1 (en) | Therapeutic agent | |
| AU2001292578A1 (en) | Pharmaceutical compounds | |
| AU2000238755A1 (en) | Dermatological compounds | |
| AU2001271999A1 (en) | Therapeutic uses for aminosterol compounds | |
| AU2001292897A1 (en) | Novel therapy | |
| AU2002216043A1 (en) | Compounds | |
| GB0013105D0 (en) | Therapeutic compounds | |
| AU7634201A (en) | 6-methyl-4-trihalomethyltriazine compounds | |
| AU2002216577A1 (en) | Therapeutic compounds |